Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
SIIC selecciona textos completos de calidad y de reciente publicación en fuentes prestigiosas del mundo
indizadas por SIIC Data Bases, capturadas en las mismas colecciones o en diversas bases especializadas.
La creciente cantidad de artículos con Acceso Abierto (Open
Access) amplía la oferta de lectura pero a su vez también, entre
tanta abundancia, complica al lector en su encuentro con los estudios
fundamentales. Para facilitarlo, profesionales biomédicos de SIIC
consultan diariamente una profusa cantidad de documentos que nutrirán
Textos completos autorizados (TCA).
Las citas de la sección TCA enlazan de manera legal, autorizada y
gratuita con los textos completos (full text) publicados en
los sitios oficiales de sus respectivas fuentes.
SIIC creó, produjo y opera con exclusividad el software TCA para la
interpretación de los diversos campos documentales que integran la
estructura de un estudio: especialidad, modalidad del estudio,
fuente, fechas de publicación y selección, definición de la fuente,
limitaciones de consulta, resumen en castellano, etc.
Si bien la mayoría de los textos seleccionados corresponden a
artículos originales, revisiones y guías, los lectores también
encontrarán comentarios, entrevistas, notas periodísticas, cartas a
autores u otros textos precursores de debates o aclaratorios.
Sociedad Iberoamericana de Información Científica (SIIC) selects
complete quality-full texts which have been recently published in
renowned sources worldwide and are indexed by SIIC Data
Bases.
The increasing number of Open Access articles widens the reading offer
but, also, such myriad complicates the readers search of fundamental
articles. To facilitate this, SIIC biomedical professionals daily
consult a profuse amount of documents that will feed
Authorized Full Texts (TCA, Spanish acronym).
The citations of the AFT section link legally, authorized and free of
charge with the full texts published in the official web sites of
their corresponding sources.
SIIC created, produced and handles the AFT software that deciphers
the various documentary fields that form part of the structure of a
study: specialty, study style, source, publication and selection
dates, source definition, query limitations, summary in Spanish,
etc.
While most of the selected texts belong to original articles,
reviews, and guidelines, readers will also find commentaries,
interviews, journalistic reports, letters to authors or other texts
that may lead to discussions or clarifications.
What is the role of out of programme clinical fellowships in the era of Shape of Training? A single-centre cohort study.
What is the role of out of programme clinical fellowships in the era of Shape of Training? A single-centre cohort study.
Fuente:Bmj Open Gastroenterology
Extracto:
Out of programme
clinical fellowships offer the opportunity to develop the required training
competencies, subspecialty expertise and research skills in a supportive
environment.
Claves:ENDOSCOPY, HEALTH SERVICE RESEARCH, SURGICAL TRAINING
Cita:BMJ Open Gastroenterol 2024 Apr 30; 11 (1)
Autor/es:Raju, Suneil A (a) Bowker-Howell, Freya J (b)
institución:(a) Division of Clinical Medicine, The University of Sheffield, Sheffield, UK suneilraju@gmail.com. (b) Academic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Risk of cancer in patients with bile acid diarrhoea
Risk of cancer in patients with bile acid diarrhoea
Fuente:Bmj Open Gastroenterology
Tipo de trabajo:Estudio de cohortes
Extracto:
Bile acid diarrhoea was associated with an increased overall risk of
cancer, especially haematological cancers, but the risk of colorectal cancer was
not increased. The lack of a diagnostic code for bile acid diarrhoea and
potential residual confounding are limitations, and the findings should be
replicated in other cohorts.
institución:(a) Department of Gastroenterology, Zealand University Hospital Koge, Koge, Denmark nynne@nyboeandersen.com. (b) Department of Gastroenterology and Hepatology, Hvidovre Hospital, Hvidovre, Denmark.
Conflicto:Competing interests: SW has served as an advisory board member for AbbVie and Bristol-Myers Squibb and received financial fees for teaching and consulting from Tillotts and Bristol-Myers Squibb. TJ has received financial fees for consulting from Ferring.
Laparoscopic Resection Combined with a Transsacral Approach for a Recurrent Tailgut Cyst with a Refractory Fistula.
Laparoscopic Resection Combined with a Transsacral Approach for a Recurrent Tailgut Cyst with a Refractory Fistula.
Fuente:Acta Medica Okayama
Extracto:
We describe a case
in which the combination of laparoscopic and transsacral approaches was effective
for resecting a recurrent refractory fistula after incomplete resection of a tail
gut cyst.
institución:(a) Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. (b) Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Conflicto:No potential conflict of interest relevant to this article was reported.
institución:(a) Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. (b) Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Conflicto:No potential conflict of interest relevant to this article was reported.
institución:(a) Department of Gastroenterological Surgery, Kochi Health Sciences Center. (b) Department of Gastroenterological Surgery, Kochi Health Sciences Center.
Conflicto:No potential conflict of interest relevant to this article was reported.
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Fuente:Brain and Behavior
Extracto:
Our nationwide registry analysis
suggests that, once escalation from a low-efficacy DMT is indicated, switching
directly to a high-efficacy treatment is superior to a stepwise escalation
starting with a moderate-efficacy treatment.
institución:(a) Neurology Clinic and Policlinic, Departments of Head, Spine and Neuromedicine, MS Center and Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland. (b) Division of Health Care Sciences, Dresden International University, Dresden, Germany.
Conflicto:Jannis Müller has nothing to disclose about this work. He has received financial support by the Swiss National Science Foundation (grant No. P500PM_214230). Izanne Roos has reported receiving grants from MSIF, MS Australia, and the Trish Multiple Sclerosis Research Foundation and served on scientific advisory boards, received conference travel support and/or speaker honoraria from Roche, Novartis, Merck, and Biogen outside...
e the submitted work. Tomas Kalincik served on scientific advisory boards for MS International Federation and World Health Organisation, BMS, Roche, Janssen, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Eisai, Novartis, Biogen, Roche, Sanofi Genzyme, Teva, BioCSL, and Merck, and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene, and Merck. Johannes Lorscheider received research support from Innosuisse‐Swiss Innovation Agency, Biogen and Novartis and served on advisory boards for Roche and Teva. Edoardo Galli declares that there is no conflict of interest. Pascal Benkert declares that there is no conflict of interest. Sabine Schädelin declares that there is no conflict of interest. Sifat Sharmin declares that there is no conflict of interest. Maximilian Einsiedler declares that there is no conflict of interest. Peter Hänni is an employee of the Swiss Federation for Common Tasks of Health Insurances Jürg Schmid is an employee of the Swiss Federation for Common Tasks of Health Insurances. Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Alnylam, Bayer, Biogen, Bristol Myers Squibb, Celgene, Immunic, Merck, Neurogenesis, Novartis, Octave Bioscience, Quanterix, Roche, Sanofi, Stata DX. Tobias Derfuss received speaker fees, research support, travel support, and/or served on Advisory Boards or Steering Committees of Alexion, Novartis, Merck, Biogen, GeNeuro, MedDay, Roche, and Sanofi Genzyme. Cristina Granziera has received the following fees which were used exclusively for research support: (i) advisory board and consultancy fees from Actelion, Genzyme‐Sanofi, Novartis, GeNeuro, and Roche; (ii) speaker fees from Genzyme‐Sanofi, Novartis, GeNeuro and Roche; (iii) research support from Siemens, GeNeuro, Roche. Cristina Granziera is supported by the Swiss National Science Foundation (SNSF) grant PP00P3_176984, the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung, and the EUROSTAR E!113682 HORIZON2020. Tjalf Ziemssen received personal compensation from Biogen, Bayer, Celgene, Novartis, Roche, Sanofi, Teva for the consulting services. Ziemssen received additional financial support for the research activities from Bayer, Biogen, Novartis, Teva, and Sanofi. Timo Siepmann received grants from the German Federal Ministry of Health, Kurt Goldstein Institut, German Parkinson Association that were not related to this study. Dr. Siepmann received royalties from Thieme as well as from Astrazeneca for consulting and from Dresden International University for serving as program director and lecturer of the Master's Program in Clinical Research. Özgür Yaldizli received grants from Swiss National Science Foundation, ECTRIMS/MAGNIMS, University of Basel, Pro Patient Stiftung University Hospital Basel, Free Academy Basel, Swiss Multiple Sclerosis Society and advisory board, lecture and consultancy fees from Roche, Sanofi Genzyme, Allmirall, Biogen, and Novartis.
institución:(a) Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Hubei, 442000, China. (b) Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Evaluation of the "Burgenland PREvention trial of colorectal cancer Disease with ImmunologiCal Testing" (B-PREDICT)-a population-based colorectal cancer screening program.
Evaluation of the "Burgenland PREvention trial of colorectal cancer Disease with ImmunologiCal Testing" (B-PREDICT)-a population-based colorectal cancer screening program.
Fuente:Bmc Gastroenterology
Extracto:
B-PREDICT shows a
two-fold higher detection rate of CRC as well as HRA compared to OPP-COL.
institución:(a) Center for Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, 1090, Austria. (b) Department of Internal Medicine, Hospital Oberpullendorf, Oberpullendorf, Austria.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Risk factors of sleep-disordered breathing and poor asthma control in children with asthma.
Risk factors of sleep-disordered breathing and poor asthma control in children with asthma.
Fuente:Bmc Pediatrics
Extracto:
Allergic rhinitis,
chronic tonsillitis, gastroesophageal reflux, adenoid hypertrophy, recurrent
respiratory infections, and a family history of snoring were independent risk
factors for the development of SDB in children with asthma. SDB and irregular
medication use were independent risk factors for poor asthma control.
Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.
Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.
Fuente:Bmc Cancer
Tipo de trabajo:Consenso
Extracto:
There was no significant difference in 5-year OS
and DFS rates between patients with early-stage cervical cancer without high-risk
factors undergoing postoperative CCRT versus RT alone. Patients who underwent
CCRT appeared to develop a higher proportion of grade ≥ 3 acute hematological
toxicities than those who underwent RT alone.
Claves:Cervical cancer, Deep stromal invasion, Large tumor size, Lymphovascular space involvement, Postoperative concurrent radiochemotherapy, Radiotherapy
Cita:BMC Cancer 2024 Apr 30; 24 (1) : 548.
Autor/es:Zhou, Yuncan (a) Wang, Weiping (b)
institución:(a) Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. (b) Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Anticancer properties and metabolomic profiling of Shorea roxburghii extracts toward gastrointestinal cancer cell lines.
Anticancer properties and metabolomic profiling of Shorea roxburghii extracts toward gastrointestinal cancer cell lines.
Fuente:Bmc Complementary Medicine and Therapies
Extracto:
This study highlights the potential of natural compounds in
Shorea roxburghii in the development of more effective and safer anticancer
agents as options for GIC as well as shedding light on new avenues for cancer
treatment.
institución:(a) Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand. (b) Regional Medical Sciences Center 2 Phitsanulok, Department of Medical Sciences, Ministry of Public Health, Phitsanulok, Thailand.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Latent profiles of fatigue in inflammatory bowel disease.
Latent profiles of fatigue in inflammatory bowel disease.
Fuente:Bmc Gastroenterology
Extracto:
Latent profile analysis identifies four classes of fatigue in an IBD
cohort with associations with specific risk factors for fatigue along with
specific IBD and demographic attributes. This has implications for the
classification of fatigue in IBD and treatment algorithms.
institución:(a) Department of Gastroenterology, Southern Adelaide Local Health Network (SALHN), Flinders Medical Centre, Flinders Drive, Bedford Park, 5042, SA, Australia. alex.barnes@sa.gov.au. (b) College of medicine and public health, Flinders University, Bedford Park, SA, Australia. alex.barnes@sa.gov.au.
Conflicto:Jane M Andrews: Speakers fees, and Ad Boards from: Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, BMS 2020, Celegene, Celltrion, Falk, Ferring, Gilead, Hospira, Im-muninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Progen-ity, Pfizer, Sandoz, Shire, Takeda, Vifor, RAH research Fund, The Hospital Research Fund 2020-2022, The Helmsley Trust 2020-2023. Reme Mountifield: Speakers fees, and Ad Boards from: Abbott, AbbVie, Allergan, Anatara, AstraZeneca,...
Bayer, BMS 2020, Celegene, Celltrion, Falk, Ferring, Gilead, Hospira, Im-muninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Progen-ity, Pfizer, Sandoz, Shire, Takeda. Rob V Bryant: has received Grant/Research support/Speaker fees (all paid to employer for research support): AbbVie, Ferring, Janssen, Shire, Takeda, Emerge Health; shareholder in BiomebankNo conflict of interest: Alex Barnes, Sutapa Mukherjee, Paul Spizzo, Barbara Toson.
Mycophenolate-induced colitis in a patient with lupus nephritis
Mycophenolate-induced colitis in a patient with lupus nephritis
Fuente:Journal of Medical Case Reports
Tipo de trabajo:Revisión
Extracto:
The purpose of this paper is to report a
case of early-onset MMF-induced colitis in a patient with lupus nephritis who had
started MMF as induction therapy. A review of the available literature on this
uncommon immunosuppressive effect is also presented.
institución:(a) Rheumatology Unit, Internal Medicine Department, King Abdul-Aziz Specialist Hospital, Taif, Saudi Arabia. Alakkas.ziyad@gmail.com. (b) Rheumatology Unit, Internal Medicine Department, King Fahad Hospital, Jeddah, Saudi Arabia.
Conflicto:The authors declare that there is no competing interests.
Application and value of anxiety and depression scale in patients with functional dyspepsia.
Application and value of anxiety and depression scale in patients with functional dyspepsia.
Fuente:Bmc Psychology
Tipo de trabajo:Orientaciones y guía
Extracto:
PHQ-9, SAS, HAMD, and HAMA scales have good application performance in FD
patients. They can assist gastroenterologists in evaluating anxiety and
depression symptoms, and provide reference and guidance for subsequent treatment.
institución:(a) The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, 1111 East Wenzhou Dadao, Longwan District, Wenzhou, 325000, Zhejiang, China. (b) The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, 1111 East Wenzhou Dadao, Longwan District, Wenzhou, 325000, Zhejiang, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
institución:(a) Key Laboratory of Microbiology and Parasitology of Education Department of Guizhou, Guizhou Medical University, Guiyang 561113, Guizhou Province, China. (b) Key Laboratory of Endemic and Ethnic Diseases of Ministry of Education, Guizhou Medical University, Guiyang 561113, Guizhou Province, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Drug-induced mucosal alterations observed during esophagogastroduodenoscopy.
Drug-induced mucosal alterations observed during esophagogastroduodenoscopy.
Fuente:World Journal of Gastroenterology
Extracto:
This minireview aims to provide essential
information on drug-induced mucosal alterations observed on
esophagogastroduodenoscopy, along with representative endoscopic images.
institución:(a) Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan. pr145h2k@okayama-u.ac.jp. (b) Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Conflicto:Conflict-of-interest statement: Iwamuro M has received lecture fees from Otsuka Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., as well as grants from Taisho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Abbott Japan Co., Ltd. Kawano S has received lecture fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., AstraZeneca PLC,...
Viatris Inc., Zeria Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd., along with grants from Taisho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Abbott Japan Co., Ltd. Otsuka M has received lecture fees from Chugai Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, AbbVie GK, EA Pharma Co., Ltd., and Kowa Company, Ltd., along with grants from Taisho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Abbott Japan Co., Ltd.
institución:(a) Department of Gastroenterology, First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China. (b) Department of Gastroenterology, First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Conflicto:Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
MicroRNAs in inflammatory bowel disease: What do we know and what can we expect?
MicroRNAs in inflammatory bowel disease: What do we know and what can we expect?
Fuente:World Journal of Gastroenterology
Extracto:
Discoveries regarding the
influence of miRNAs on the inflammatory process and the exploration of their role
in gene regulation are expected to provide a basis for the use of miRNAs not only
as potent biomarkers in IBD but also as therapeutic targets for the control of
inflammatory processes in personalized medicine.
Autor/es:de Oliveira, Ellen Cristina Souza (a) Quaglio, Ana Elisa Valencise (b)
institución:(a) Department of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, São Paulo, Brazil. (b) Verum Ingredients, Botucatu Technology Park, Botucatu 18605-525, São Paulo, Brazil.
Conflicto:Conflict-of-interest statement: The authors report having no relevant conflicts of interest for this article.
Alergia
Anestesiología
Bioquímica
Cardiología
Cirugía
Dermatología
Endocrinología y Metabolismo
Enfermería
Gastroenterología
Hematología
Infectología
Inmunología
Medicina Interna
Nefrología
Neumonología
Neurología
Nutrición
Obstetricia y Ginecología
Odontología
Oncología
Otorrinolaringología
Pediatría
Salud Mental
Salud Pública
Urología
Más Especialidades
